Rapt Therapeutics Inc (RAPT) is trading 9% higher at $31.875 today. While it's a mildly green day for the Health Care sector in general, the stock is quickly outshining it's peers. A few weeks ago they reported earnings:

Rapt Therapeutics Inc has been trading between a 52-week high of $40.74 and a 52-week low of $9.86. The stock has a market cap of $945 Million.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

Recap: RAPT Therapeutics Q2 Earnings
Benzinga 08-11-22

RAPT Therapeutics GAAP EPS of -$0.62 beats by $0.12, revenue of $0.89M beats by $0.58M
Seeking Alpha 08-11-22

RAPT Therapeutics Reports Second Quarter 2022 Financial Results
GlobeNewswire 08-11-22

RAPT Therapeutics Inc. (NASDAQ: RAPT): Can A Stock Be Down -44.02% YTD, And Still Be A Loser
Marketing Sentinel 07-09-22

MyMD, Clovis top healthcare gainers; while RAPT, Veru lead losers'' pack
Seeking Alpha 07-08-22